ArticleNeuroepidemiology2025
The Pathology, Alzheimer's and Related Dementias Study (PARDoS): Design and Characteristics of the First 4,700+ Brazilian Participants.
Article in Neuroepidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
introductionThe Pathology, Alzheimer's and Related Dementias Study (PARDoS) is a community-based clinical-pathologic study of aging and dementia in a large and diverse sample of Brazilians. Its long-term objective was to identify the environmental, genetic, and molecular drivers of common conditions across the adult life span with an emphasis on Alzheimer's disease and related disorders clinical and neuropathologic traits.
methodsFrom July 31, 2021, through February 11, 2025, 4,790 brains were collected at two autopsy centers and a major hospital system in the State of São Paulo, Brazil. Samples of other organs are also being collected. Their mean age was 71.7 years (range 18-106), 40.2% were black/mixed, 52.7% were male, their mean education was 6.3 years (range 0-25). Among those aged 65+, 32.9% had dementia and 18.8% had mild cognitive impairment. Neuropathologic data collection is ongoing.
conclusionPARDoS fills several major gaps among clinical-pathologic studies given the large numbers and its unique age and education range and socioeconomic status, race, sex, and other organ collection. Here, we present the study design, demographic characteristics of the first 4,790 autopsied participants, and clinical characteristics of the first 4,283 with informant interviews.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.